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ABSTRACT
Bone morphogenetic proteins (BMPs) participate in multiple stages of the fetal skeletogenic program from promoting cell condensation
toregulatingchondrogenesisandboneformationthroughendochondralossification.Here,weshowthatthesepleiotropicfunctionsare
recapitulated when recombinant BMPs are used to augment skeletal tissue repair. In addition to their well-documented ability to
stimulate chondrogenesis in a skeletal injury, we show that recombinant BMPs (rBMPs) simultaneously suppress the differentiation of
skeletal progenitor cells in the endosteum and bone marrow cavity to an osteoblast lineage. Both the prochondrogenic and
antiosteogenic effects are achieved because rBMP inhibits endogenous b-catenin-dependent Wnt signaling. In the injured periosteum,
this repression of Wnt activity results in sox9 upregulation; consequently, cells in the injured periosteum adopt a chondrogenic fate. In
the injured endosteum, rBMP also inhibits Wnt signaling, which results in the runx2 and collagen type I downregulation; consequently,
cells in this region fail to differentiate into osteoblasts. In muscle surrounding the skeletal injury site, rBMP treatment induces Smad
phosphorylation followed by exuberant cell proliferation, an increase in alkaline phosphatase activity, and chondrogenic differentiation.
Thusdifferentpopulations ofadultskeletalprogenitorcellsinterpret thesamerBMPstimulus inuniqueways,andtheseresponsesmirror
the pleiotropic effects of BMPs during fetal skeletogenesis. These mechanistic insights may be particularly useful for optimizing the
reparative potential of rBMPs while simultaneously minimizing their adverse outcomes.  2010 American Society for Bone and Mineral
Research.
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Introduction
I
n the last quarter century, substantial progress has been made
toward understanding the molecular machinery governing
fetalskeletal tissuedevelopment.Analysesofhumanandmurine
skeletal phenotypes have led to the identification of transcrip-
tional regulators of chondrogenic and osteogenic cell fate
commitment.
(1–4) Careful scrutiny of the fetal growth plate has
revealed novel interactions between growth factors, hormones,
and matrix-remodeling enzymes that synchronize chondrocyte
maturation with angiogenesis.
(5–7) In addition, new regulators of
skeletogenesis have been identified in large-scale genomic and
microarray screens.
(8–10) Collectively, these data have provided




determine how these observations can be translated into
therapeutic strategies to enhance adult skeletal tissue regenera-
tion. Such strategies are often built on the basic principles
underlying embryonic bone development because it has
become increasingly evident that the mechanisms controlling
fetal bone formation are similar to the mechanisms regulating
adult bone repair and bone remodeling. The time scale and
the distribution of bone-forming activity are different, but the
cellular and molecular mechanisms governing chondrocyte,
osteoblast, and osteoclast function are indistinguishable.
Consequently, studies that investigate how undifferentiated
pluripotent embryonic cells choose to proliferate versus adopt a
chondrogenic or an osteogenic fate provides a ‘‘window’’ into
that same decision that occurs as part of adult repair and
remodeling.
Bone morphogenetic proteins (BMPs) were originally dentified
asan‘‘activity.’’Uristdiscoveredthatsoonafterimplantationintoa
musclepouch,decalcifiedbonereleasedasubstancethatinduced
host cells to differentiate into chondrocytes.
(12,13) This osteoin-
ductive effect is now attributable to the action of BMPs. The
subsequent cloning and characterization of vertebrate BMPs
revealed their pleiotropic functions. For example, BMPs are
requiredfortheearlieststepinskeletaltissueformation,whencells
undergo condensation.
(14) BMPs also are required for multiple
ORIGINAL ARTICLE J JBMR
Received in original form April 27, 2009; revised form September 18, 2009; accepted January 6, 2010. Published online January 15, 2010.
Address correspondenceto:JillAHelms,DDS,PhD,Department ofSurgery,Division ofPlasticandReconstructiveSurgery, StanfordSchoolofMedicine, 257Campus
Drive, GK 207, Stanford, CA 94305, USA. E-mail: jhelms@stanford.edu
Journal of Bone and Mineral Research, Vol. 25, No. 6, June 2010, pp 1196–1207
DOI: 10.1002/jbmr.29
 2010 American Society for Bone and Mineral Research
1196steps in the program of chondrogenesis by acting through
Smads
(15) to regulate Msx transcription factors and collagen gene
expression.
(16) BMPs also regulate fetal osteogenesis, in part,
through their inhibitory effects on Wnt pathway activation.
(17)
The striking ability of BMPs to induce endochondral
ossification led to the development of recombinant proteins
for the treatment of skeletal injuries and to augment autologous
bone grafting. While some clinical studies indicate that
recombinant BMPs stimulate bone healing,
(18) there remains a
significant disparity between the impressive results obtained in
animal models and the less stellar effects observed in human
trials.
(19–21) In addition, their off-label use has led to a number of
unanticipated and detrimental side effects.
(22)
The basis for a disparity between human clinical data and
preclinical trials in animals is unclear. Differences have been
variously attributed to the method of recombinant BMP (rBMP)
delivery, the number of responding cells at the implant site, and
the extent of the skeletal injuries in animal models versus in
humans. These explanations, however, cannot fully explain the
discrepancies. The same delivery methods and delivery vehicles
were used in preclinical trials and in animal models, but the
effects on bone healing were dramatically different.
(18,23–27)
Furthermore, the efficacy of rBMPs was demonstrated in critical-
size defects in animals that are comparable in severity to tibial
nonunions in humans.
(19,28)
Perhaps the most difficult issue to resolve is whether rBMPs
have skeletal stem cell–specific effects. For example, in both
human and mouse bone injuries, skeletal progenitor cells arise
from multiple tissue compartments including the injured
periosteum, endosteum, bone marrow cavity, vascular tissue,
and surrounding musculature.
(29–31) All these progenitor
populations contribute cells to the healing skeletal injury, but
whether they respond equivalently to rBMP is not known. We
devised a skeletal injury model in which the contributions from
these various tissue compartments could be readily distin-
guished from one another and then employed the same delivery
method as is used in humans to treat the skeletal injuries with
rBMP-2. Using transgenic mice and molecular and cellular
analyses, we discovered that rBMP-2 represses endogenous b-
catenin-dependent Wnt signaling. In the injured periosteum,
repression of Wnt activity permits sox9 and collagen type II
upregulation followed by exuberant chondrogenesis. In the
injured endosteum, however, repression of Wnt activity blocks
runx2 and collagen type I expression, leading to an arrest in
osteoblast differentiation. In the surrounding musculature, rBMP
induces phosphorylation of Smad 1/5/8 in muscle cells, which
respond by proliferating and adopting a chondrogenic fate.
These data from an adult injury site closely parallel the diverse
functions of BMPs in fetal skeletal development and provide a






responsiveness. Inthis mouse, the Wnt target Axin2 wasreplaced
with a copy of LacZ with an Axin2 promoter.
(32,33) Adult Axin
lacZ/þ
heterozygote mice were used in this study.
Monocortical defect model
All procedures were approved by the Stanford Committee on
Animal Research. These studies were conducted on mice
between 2 and 5 months of age. We employed a monocortical
tibial defect model to evaluate bone repair. After an appropriate
level of anesthesia was reached, an incision was made over the
anteroproximal tibia, and the tibial surface was exposed while
simultaneously preserving the periosteal surface. A drill hole was
created through a single tibial cortex with a high-speed dental
engine (15,000rpm) using a 1.0-mm drill bit (Drill Bit City,
Chicago, IL, USA). The free edge of the cut muscle flap was
replaced over the injury site with a single stitch, and the wound
was closed surgically. Following surgery, mice received 0.1-mL
subcutaneous injections of sterile saline and were allowed to
ambulate freely.
Sample preparation
Tibiae were harvested and skinned at the appropriate time
points and decalcified in 19% EDTA until fully decalcified.
Samples to be stained for Xgal activity then were soaked
overnight in 30% sucrose and cryoembedded in 22-oxacalcitrol
(OCT). These samples were sectioned at a thickness of 10mm. All
other samples were dehydrated in a graded ethanol series after
decalcification. These samples then were soaked in xylene
followed by paraffin. These paraffin-embedded samples then
were sectioned at a thickness of 8mm.
Modified periosteal injury model
The monocortical defect was modified so that neither cortex was
penetrated, leaving the bone marrow cavity uninjured. After an
appropriate level of anesthesia was reached, an incision was
made over the anteroproximal tibia, and the tibial surface was
exposed while preserving the periosteal surface. Here, a 1-mm
dremel drill bit was used with a drill engine to injure the
periosteum of one cortex. The procedure resulted in the removal
of an approximately 0.5mm diameter piece of cortical bone; the
bone marrow cavity was untouched.
Delivery of rBMP-2
In treatment of the monocortical tibial defect, absorbable
collagen hemostatic sponges (Integra LifeSciences Corporation,
Plainsboro, NJ, USA) werecut to the dimensions of the injury site.
Sponges were soaked in 1mL of recombinant BMP-2 (Med-
tronics, Minneapolis, MN, USA) at a concentration of 1mg/mL for
30 minutes at 48C. After the drill injury was placed but before the
muscle was apposed, the loaded sponge was inserted into the
marrow space.
In treatment of the modified periosteal injury, the absorbable
collagen hemostatic sponge was cut to twice the volume as
specified earlier. This stabilized the sponge at the injury site and
separated the muscle tissue from the periosteal tissue. The
sponge was soaked in 2mL of rBMP-2 and placed over the
periosteal injury. The free edge of the muscle flap was secured
BMP IN BONE REGENERATION Journal of Bone and Mineral Research 1197over the sponge to the lateral tibial muscles as before, holding
the sponge in place.
Cellular analyses
Immunohistochemistry: The following description is a general
procedure that we use for localization of protein within tissue
sections; the precise protocol depends on the antibody being
used. In general, tissue sections were dewaxed, followed by
immersion in H2O2/PBS and washing in PBS. The sections were
permeabilized with Ficin, followed by treatment with 0.1M
glycine. After further washing in PBS, the sections were blocked
in ovalbumin or whole donkey IgG. Appropriate primary
antibody was added and incubated overnight at 48C and then
washed in PBS. Samples were incubated with peroxidase-
conjugated secondary antibody (Jackson Immunoresearch, West
Grove, PA, USA) for 1 hour. DAB Kit (VectorLab, Burlingame, CA,
USA) was used to develop color reaction. Here, we used
antibodies to platelet endothelial cell adhesion molecule
(PECAM) and proliferating cell nuclear antigen (PCNA).
Evaluating b-galactosidase activity: Tissue of interest was
cryosectioned, fixed in 0.8% glutaraldehyde, and incubated with
Xgal substrate overnight at 378C.
Quantifying Wnt responsiveness:  40 images of endosteum or
periosteum adjacent to injury sites were taken. The injured
cortical edge was used as a reference point to standardize the
region of interest. Xgal
þ cells were counted in the endosteal/




All hybridization steps were done in RNase-free conditions.
Tissue was embedded in paraffin and cut into 8.0-mm sections.
Sections were dewaxed and washed in PBS. Sections then were
treated with 0.2N HCl and washed in PBS. Then sections were
treated with proteinase K, washed in PBS, fixed in 4%
paraformaldehyde, and washed again in PBS. Sections were
treated with 0.5% acetic acid in 0.1M trietholamine, washed, and
dehydrated. The sections were incubated overnight at 528C with
the antisense RNA probe of interest in combination with in situ
hybridization buffer (Ambion, Foster City, CA). All RNA probes
were constructed antisense to the RNA sequence of interest and
transcribed using digoxigen-labeled ribonucleotides and stored
in hybridization buffer. Probes were used at approximately
1.0mg/mL.
The sections were treated with stringency solutions of
formamide, sodium citrate, and Tween-20 to remove unhybri-
dizedprobe.Thesectionsthenwerewashedinmaleicacidbuffer
(pH 7.5) and blocked with 2% blocking reagent (Roche,
Indianapolis, IN, USA) and 10% lamb serum. Sections then were
incubated with alkaline phosphatase–conjugated, anti-DIG Fab
fragments in 2% blocking reagent and 1% lamb serum overnight
at 48C. Sections then were treated with tetramisole (Sigma, St.
Louis, MO, USA) to block endogenous alkaline phosphatase and
incubated in NTMT buffer with 10% polyvinyl alcohol (Sigma), 4-
nitro blue tetrazolium (Roche), and 5-brom-4-chloro-3-indoyl-
phosphate (Roche) to develop the color reaction.
Histology and histomorphometry
Pentachrome and aniline blue were used to detect osseous
tissues, as described previously.
(34,35) Tibiae were collected on
postoperative days 3, 6, and 14 to determine the volume of new
bone in PBS and rBMP-2 samples. This was accomplished by
generating paraffin sections, tissues were stained with aniline
blue, and representative sections were analyzed as described
below. In total, three to six tibiae were used for each condition.
The 1.0-mm circular monocortical defect was represented
across approximately 120 tissue sections, each of which was
8mm thick. Approximately 40 slides were generated from
sections, and six to eight tissue sections were used for
histomorphometric analysis. Each section was photographed
using a Leica digital imaging system ( 5 objective). The digital
images were imported into Adobe Photoshop CS2 (Adobe
Systems, Inc., San Jose, CA). The region of interest typically
encompasses 10
6 pixels. The number of aniline blue–stained
pixels was determined using the Magic Wand tool (tolerance
setting: 60; histogram pixel setting: cache level 1) by a single
blinded investigator and confirmed by a second independent
investigator. These data then were used to calculate the total
volume of new bone in each callus. For quantifying the cartilage,
safranin-O was used to stain proteoglycan-rich cartilage, and the
preceding histomorphometry procedure was used with slight
differences. Specifically, the tolerance was set to 40.
Statistical analysis
A Student’s t test was used to quantify differences described in
this article. Error bars represent standard deviation. A number
symbol (
#) denotes a p value of less than .05, and an asterisk (
 
)
denotes a p value of less than .01.
Results
rBMP-2 potentiates endochondral ossification in a
skeletal injury
A skeletal defect model was used to investigate how rBMP-2
affected skeletal progenitor cells during the process of bone
regeneration. This model was chosen because it effectively
separates cellular contributions from the periosteum, the
endosteum, and the surrounding muscle from the regenerative
process.
(34,36) Skeletal injuries were treated with rBMP-2-soaked
sponges as specified by the manufacturer and as described in
other animal models
(26,37,38) and in humans.
(24)
On postoperative day 6, rBMP-2-treated samples exhibited a
large cartilage callus, whereas PBS-treated samples showed only
a small region of cartilage (n¼6 for each condition; Fig. 1A,B).
Histomorphometric measurements demonstrated that rBMP-2
samples had a 31-fold increase in the cartilage callus volume
compared with PBS controls (Fig. 1C). In the PBS-treated injury
site, cartilage was evident only in the injured periosteum (yellow
dotted line, Fig. 1D). In contrast, rBMP-2 samples exhibited two
domains of cartilage: One domain extended from the cortical
surface to a fibrous/adipogenic layer (i.e., domain I); the other
cartilage domain extended from the fibrous/adipogenic layer to
the subcutaneous tissue (domain II, Fig. 1E). In PBS controls,
1198 Journal of Bone and Mineral Research MINEAR ET AL.Fig. 1. rBMP-2 induces a large extracortical callus via endochondral ossification. (A) safranin-O/fast green staining on postoperative day 6 cartilage in the
PBS-treated injured periosteum signaling endochondral ossification (dotted lines). (B) rBMP-2 treatment induces a large cartilage callus superficial to the
cortex.(C)Histomorphometric measurementsshowthatcomparedwithPBS,rBMP-2inducesa31-foldincreaseinthesizeofthecartilagecallus.(D)A 40
view of safranin-O/fast green staining reveals minimal cartilage in the periosteal reaction (po) to injury in PBS-treated samples. (E) rBMP-2 treatment
induces two large cartilaginous domains. One is the periosteal reaction (I) and the other is superficial (II) and is separated from one another by adipose/
fibroustissue(asterisks).( F)PCNAstainingrevealsproliferationinboththesupraperiosteumandperiosteuminPBS-treatedcontrols.(G)rBMP-2treatment
reveals two domains of proliferating cells, a periosteal reaction and a second, supraperiosteal response. (H) Postoperative day 14 aniline blue staining of
control samples shows robust osteogenesis in the bone marrow cavity (dotted line). (I) rBMP-2-treated samples exhibit a large bony callus located
exclusively in the extracortical space; bone formation in the injury site is not detectable. (J) rBMP-2 treatment induces a 6-fold increase in the size of the
bony callus. (K) In PBS-treated samples, aniline blue staining reveals the periosteal reaction on postoperative day 14. (L) By postoperative day 14, the two
cartilage domains have coalesced into a single bony domain in the rBMP-2-treated samples (white bracket). ps¼postsurgical; ad¼adipogenic;
cb¼cortical bone; is¼injury site.
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teum (i.e., domain I, Fig. 1F), whereas rBMP-2 samples showed
robust PCNA immunostaining in domains I and II (Fig. 1G). Thus
rBMP2 treatment induced cells in the periosteum and
supraperiostealspacetoproliferateandtoadoptachondrogenic
fate.
On postoperative day 14, new bone occupied the PBS-treated
bone marrow cavity, and the fibrocartilaginous tissue arising
from the injured periosteum had been replaced by bone (n¼4;
dotted line, Fig. 1H). rBMP-2-treated injury sites showed a
different response: No new bone was present in the bone
marrow cavity, and the entire extracortical region was
encapsulated in a large bony callus (n¼3; dotted line, Fig. 1I).
Histomorphometric measurements demonstrated that com-
pared with PBS-treated controls, rBMP-2-treated samples had a
6-fold increase in the total amount of newly regenerated bone
(Fig. 1J).
The location of the regenerate also provided clues as to the
origins of the new bone. For example, in PBS-treated controls,
new bone was found primarily in the bone marrow cavity
(Fig. 1H), indicating its origin from osteoprogenitor cells in the
endosteum.
(36) A small amount of new bone was detectable in
the periosteal region of the PBS-treated samples (Fig. 1K), which
likely arises from osteoprogenitor cells in the periosteum.
(39) In
rBMP-2-treated samples, the bony regenerate was found
exclusively in the extracortical region (Fig. 1L), indicating its
derivation from the periosteum and from the surrounding soft
tissues. No new bone (or cartilage) was detected in the bone
marrow cavity. To understand the molecular basis for these
disparate effects, we examined each domain in more detail,
focusing first on the bone marrow cavity and then on the
extracortical domains.
rBMP-2 prevents intramembranous ossification in the
bone marrow space
Normally, after injury, cells in the bone marrow cavity proliferate
and then differentiate into osteoblasts and deposit a mineralized
matrix (Fig. 2A, asterisks). This response was not observed in
rBMP-2-treated injuries (Fig. 2B). We evaluated each injury site
thoroughly but did not observe bone matrix in the bone marrow
cavityofrBMP-2-treatedsamples(n¼3).Tounderstandthebasis
for this differential response in the bone marrow cavity, we
examined injuries at earlier time points. On postoperative day 6,
remnants of the collagen sponges still were evident both PBS-
and rBMP-2-treated injury sites, but PBS-soaked sponges were
filled with cells and their extracellular matrix (Fig. 2C). rBMP-2
soaked sponges showed little cellular infiltrate (Fig. 2D). Cells in
the PBS-soaked sponges were proliferating (Fig. 2E), whereas no
PCNA immunostaining was detectable in the rBMP-2-soaked
sponges (Fig. 2F). These results are in striking contrast to the
robust cell proliferation elicited by rBMP-2 in the injured
periosteum (Fig. 1); here, cells in the bone marrow cavity showed
almost no proliferation in response to the same rBMP-2 stimulus.
Normally, by postoperative day 6, cells in the bone marrow
cavity have begun to differentiate into osteoblasts, which was
illustratedbythebroaddomainofosteopontin expressioninPBS-
treated samples (Fig. 2G). Osteopontin expression was not
detected in the bone marrow cavity of BMP-2-treated samples
(Fig. 2H). PBS-treated samples also showed evidence of robust
alkaline phosphatase activity in the bone marrow cavity (Fig. 2I).
Alkaline phosphatase activity was lower in rBMP-2-treated
samples (Fig. 2J). These two assays indicated that rBMP-2
treatment caused cells in the endosteum and bone marrow,
which normally contribute to the bony regenerate, to arrest prior
to their differentiation into osteoblasts. Consequently, these cells
did notcontributetothebonyregenerate,as theydidinthePBS-
treated samples. We also noticed that rBMP-2-treated samples
had more robust TRACP activity than PBS samples (Fig. 2K, L),
which is in keeping with reports of BMP-mediated activation of
osteoclasts.
(21,40) Taken together, these data demonstrated that
rBMP-2 exposure blocked the osteogenic differentiation of cells
from the endosteum and bone marrow. We next explored the
molecular basis for this cellular response.
rBMP-2 represses osteoblast differentiation in a site-
specific manner
PBS- and rBMP-2-treated samples were collected on post-
operativeday3,astageduringthehealingprocessthatprecedes
overt osteogenesis (Fig. 3A, B). We made three discoveries. First,
using phospho-Smad 1/5/8 immunostaining, we confirmed that
cells in the injured bone marrow cavity responded to rBMP-2; in
comparison, cells in the PBS-treated samples showed very little
phospho-Smad immunoreactivity (Fig. 3C, D). Second, we
determined that rBMP-2 treatment inhibited endogenous Wnt
signaling. We first used an antibody to the phosphorylated form
of b-catenin, which identifies the protein when it is targeted for
degradation. The specificity of the antibody was demonstrated
by the immunolabeling of chondrocytes in the growth plate
(Supplemental Fig. 1A, B), but the antibody showed only
nonspecific staining in the injured bone marrow (Supplemental
Fig. 1C, D). We also tested an antibody to dephosphorylated b-
catenin that identifies the protein in its active state. The
specificity of the antibody was confirmed by positive immu-
nostaining in growth plate osteoblasts (Supplemental Fig. 1E, F),
but again, the injured bone marrow cavity showed only
nonspecific staining (Supplemental Fig. 1G, H).
We then employed a genetic approach to determine if rBMP-2
treatment affectedtheendogenous Wntpathway.Wedidthisby
generating skeletal injuries in Axin2
LacZ/þ transgenic mice, in
which the LacZ gene is under control of the Wnt target Axin2.
(33)
The LacZ gene product, which is detected by Xgal staining,
therefore serves as a readout of b-catenin-dependent Wnt
activation.
(41,42) In PBS-treated samples, the endosteal region of
the bone marrow cavity adjacent to the injury site was Xgal
þ
(Fig. 3E). In rBMP-2-treated samples, Xgal activity was minimal or
undetectable (Fig 3F). Quantification of Xgal activity confirmed
the significant decrease in Wnt responsiveness in the rBMP-2-
treated samples (p<.05; Fig. 3G). This significant reduction in
Xgal activity also was seen on postoperative day 4 (p<.01;
Fig. 3G).
Wnt signaling is required for bone formation in the injury
marrow cavity.
(34) In PBS-treated samples, the distribution of
Xgal
þ cells coincided with the expression of collagen type I
(Fig. 3H) and runx2 (Fig. 3J), two markers of early osteoblast
1200 Journal of Bone and Mineral Research MINEAR ET AL.differentiation. In addition, PBS-treated samples showed evi-
dence of robust alkaline phosphatase activity (Fig. 3L), an
indicator of mineralization.
(43) In rBMP-2-treated samples, there
was no detectable expression of either collagen type I (Fig. 3I)o r
runx2 (Fig. 3K) and only minimal alkaline phosphatase activity
(Fig. 3M). As observed previously (Fig. 2J), rBMP-2-treated
samples showed more robust TRACP activity than controls
(Fig. 3N compared with Fig. 3O), but this increased osteoclastic
activity was not associated with an osteogenic response in the
bone marrow cavity (Fig. 2). The basis for this BMP-mediated
effect on osteoclastogenesis was explained in part by changes in
the expression of RANKL, a positive regulator of osteoclastogen-
esis, and osteoprotegrin (OPG), a negative regulator of the same
program.
(44) Relative to PBS-treated controls, the rBMP-2-treated
samples showed an increase in RANKL immunostaining and a
reduction in OPG immunostaining (Supplemental Fig. 2 A–D).
Thus rBMP-2 treatment represses endogenous Wnt signaling in
the bone marrow cavity, leading to repression of osteoblast
differentiation and block of bone regeneration in this locale.
A molecular basis for rBMP-2-induced ectopic ossification
Simultaneous with its repression of osteogenesis in the bone
marrow cavity, rBMP-2 treatment stimulated a robust chondro-
genic response from periosteal cells (Fig. 1). Analyses on
postoperative day 3 provided insights into how this response
was elicited. The initial cellular response appeared equivalent
between PBS- and rBMP-2-treated samples (Fig. 4A, B), but as it
had in the bone marrow cavity, rBMP-2 repressed endogenous
Wnt activity in the periosteum (Fig. 4C, D). Quantification of Xgal
demonstrated that rBMP-2-treated samples had significantly less
Wnt signaling activity than PBS-treated controls (p<.01; Fig. 4E).
Staining for phosphorylated b-catenin demonstrated a pre-
ponderance of immunopositive cells in the rBMP-2-treated
samples compared with the PBS-treated controls (Fig. 4F, G).
Thus rBMP-2 inhibited endogenous Wnt signaling in the injured
periosteum.
Wnt signaling represses sox9,
(45) a transcriptional regulator of
chondrogenesis.
(46) Accordingly, in rBMP-2-treated samples,
where endogenous Wnt signaling is repressed, we found
stronger expression of sox9 in the injured periosteum (Fig. 4I).
PBS-treated controls, which exhibit robust Wnt signaling in the
injured periosteum, showed very little sox9 expression (Fig. 4H).
Sox9 directly regulates collagen type II transcription
(47);
as expected, rBMP-2-treated samples showed an upregulation
in collagen type II expression relative to PBS-treated controls
(Fig. 4J, K).
Both PBS- and rBMP-2-treated samples showed strong
expression of collagen type I in the injured periosteum
(Fig. 4L, M). In the rBMP-2-treated samples, the collagen type I
Fig. 2. rBMP-2doesnotinduceboneformationinthemarrowcavity.(A)In controls,newboneformsprimarilyin thebonemarrowcavity,whichbeginsto
bridge the defect (asterisks), but (B) in rBMP-2-treated samples, there is no evidence of osteoid matrix in this location. (C, D) Pentachrome staining on
postoperative day 6 reveals no obvious differences in the placement of the collagen sponge, the extent of cellular infiltrate, or the amount of
vascularization between control and rBMP-2-treated samples. Despite their histologic equivalency, (E, F) the number of PCNA-immunopositive cells is
increasedincontrolscomparedwithrBMP-2-treatedsamples.Inaddition,(G,H)controlsshowhigherlevelsofosteopontinexpressionthanrBMP-2-treated
samples. (I) PBS-treated controls also show more extensive alkaline phosphatase activity than (J) rBMP-2-treated samples. Insets in panels I and J illustrate
equivalent levels of alkaline phosphatase staining in the growth plates of both tissue sections. In contrast, (K, L) TRAP activity is reduced in controls
compared with rBMP-2-treated samples. Dotted line outlines cortical bone. ps¼postsurgical; cb¼cortical bone; spg¼sponge.
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indicates the commitment of skeletal progenitor cells to a
chondrogenic lineage.
(48,49) The domain of alkaline phosphatase
activity also was expanded in rBMP-2-treated samples relative to
PBS-treated controls (Fig. 4N, O). Thus rBMP-2 treatment
inhibited endogenous Wnt signaling in the injured periosteum
that coincided with an up regulation in sox9 and collagen type II
and a robust chondrogenic response.
We also evaluated how cells in the supraperiosteal region
responded to rBMP-2. Injury sites are closed by apposition of a
muscle flap, which places this tissue in proximity to the sponge.
On postoperative day 1, cells within the muscle flap responded
to rBMP-2 as demonstrated by punctate phospho-Smad1/5/8
immunostaining; PBS-treated muscle flaps exhibited no immu-
nopositivecells(Fig.5A,B).InrBMP-2-treatedsamples,cellsinthe
muscle flap had begun to differentiate into chondrocytes, as
indicated by the coexpression of sox9, collagen type II, and
collagen type I (Fig. 5D, F, H, respectively). These chondrogenic
and osteogenic markers were not detectable in the muscle flaps
of PBS-treated samples (Fig. 5C, E, G). Even using a modified
injury that did not penetrate the cortex, supraperiosteal cells
responded to the rBMP-2 stimulus by proliferating and under-
going chondrogenesis (Fig. 5I, J). Collectively, these data
demonstrate that rBMP-2 treatment stimulated cells in the
muscle flap to adopt a chondrogenic fate and contribute to the
heterotopic callus that formed in the extracortical region.
Fig. 3. rBMP-2 suppresses differentiation of osteoprogenitors in the bone marrow cavity. (A, B) Pentachrome staining of the bone marrow cavity
on postoperative day 3 shows evidence of the collagen sponge carrier as well as a dense cellular mass with abundant red blood cells. PBS-treated
controls show more extracellular matrix than rBMP-2-treated samples. (C) Immunostaining for phospho-Smad 1/5/8 reveals no cells responding to a
BMP-2 stimulus. (D) More cells, relative to controls, are responding to rBMP-2 in the endosteum of rBMP-2-treated samples on postoperative day 3.
(E) Axin2
lacZ/þ mice were used to map b-catenin-dependent Wnt signaling in the bone marrow cavity. PBS-treated control endosteum demonstrates
extensive Wnt responsiveness. ( F) rBMP-2 abrogates the b-catenin-dependent Wnt responsiveness in the endosteum. (G) Quantification reveals
a statistically significant reduction of Wnt responsiveness on postoperative days 3 and 4. (H, J) Control samples demonstrate expression of early
markers of osteogenesis, including collagen type I and runx2, whereas (I, K) rBMP-2-treatedsamples exhibitlower levels of gene expression.(L) PBS-treated
samplesshow robust alkalinephosphataseactivity in the marrowspace, but (M) rBMP-2downregulates this activity.(N, O) rBMP-2-treated samplesexhibit
more TRAP activity than PBS-treated samples. Dotted line outlines cortical bone. cb¼cortical bone; en¼endosteum; spg¼sponge; bm¼bone marrow.
#p<.05;
 p<.01.
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Tissue regeneration increasingly is viewed as reactivation of
developmental processes, but despite their similarities, there are
significant differences as well. For example, postnatal skeleto-
genesis is influenced by the inflammatory response,
(50) the
mechanical environment,
(51) innate differences among progeni-
tor cell populations,
(39,52) and a cell’s state of differentiation at
the time of exposure.
(39) Thus it would be imprudent to assume
that the regulatory functions of BMPs are equivalent across all
stages and all locations of skeletogenic cell differentiation.
With an objective towards translating insights from develop-
ment into regenerative strategies, we examined the effects of
rBMP on skeletal progenitor cells within a stereotypical injury
site. Our data provide a mechanistic explanation for the
apparently unpredictable responses observed in humans
following use of rBMP. By employing an injury model in which
skeletal stem/progenitor cell contributions could be distin-
guished from one another, we demonstrated that rBMP-2 has
different effects depending on whether the progenitor cells
originated from the periosteum, the endosteum and bone
marrow cavity, or the surrounding musculature (Fig. 6).
rBMP-2 inhibits osteoblast differentiation in the bone
marrow cavity
There is a well-established feedback loop between BMP and Wnt
signaling,
(53,54) and Wnt signaling is a prerequisite for bone
formation
(55) and bone regeneration.
(34,56) Accordingly, we
tested whether rBMP-2 treatment blocked Wnt signaling and
found that in both the injured bone marrow cavity and the
injured periosteum, rBMP-2 treatment repressed endogenous
Wnt signaling. This same feedback loop operates during fetal
bone formation.
(17) These data have clinical implications: There is
accumulating evidence that activators of the Wnt pathway may
be effective proosteogenic stimuli.
(57) Consequently, the inhibi-
tory effects of rBMP on Wnt signaling may be detrimental (i.e., in
conditionswhereintramembranousossificationispreferred),but
in other cases, where chondrogenesis is favored, it may be
beneficial.
Fig. 4. rBMP-2inducesdifferentiationofchondrocytesandupregulatesosteochondroprogenitormarkersintheextracorticalspace.Onpostoperativeday
3, (A, B) pentachrome staining reveals a similar periosteal reaction in PBS- and rBMP-2-treated samples. (C) Axin2
lacZ/þ mice show an extensive distribution
of b-catenin Wnt responsiveness in the injured periosteum. (D) rBMP-2 treatment abrogates this Wnt responsiveness here. (E) Quantification reveals a
statistically significant reduction of Xgal
þ cells on postoperative day 3. This difference is no longer present by day 4. ( F) PBS-treated periosteum
demonstrates minimal sox9 expression of day 3. (G) rBMP-2-treated samples demonstrate a more robust and wider distribution of sox9 expression in the
periosteum. (H, I) Relative to PBS treatment, rBMP-2-treated samples exhibit higher collagen type II expression in the periosteum. (J, K) PBS- and rBMP-2-
treated samples show similar collagen type I expression in the periosteum. (L, M) Relative to PBS-treated controls, rBMP-2-treated samples exhibit higher
alkaline phosphatase activity in the periosteum. po¼periosteum.
 p<.01.
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further attention. Autologous bone marrow has inherent
osteogenic potential,
(58) and because of its limited availability,
(59)
investigators have searched for ways to augment or enhance its
osteogenic capacity. In preclinical experiments, addition of
rBMP-2tobonemarrowaspiratedoesnotenhanceosteogenesis.
For example, rBMP-2 added to human bone marrow stromal cell
cultures does not induce alkaline phosphatase activity and
requires additional factors such as dexamethasone to induce
osteoblast differentiation.
(60–62) Likewise, the addition of rBMPs
does not increase the osteogenic potential of grafted cancellous
bone.
(21,63)
Our data provide mechanistic insights into this antiosteogenic
effect. In our model, rBMP-2-soaked sponges repressed
osteogenesis in the endosteum and bone marrow cavity (Figs.
1 and 2). If left untreated, cells in the endosteum and bone
marrow cavity normally differentiate into osteoblasts and
generate new bone via intramembranous ossification (Figs. 1
and 2). rBMP-2 did not induce bone marrow cells to adopt a
chondrogenic fate either,because collagen typeIIexpressionwas
undetectable (data not shown), and we did not find evidence of
overt chondrogenesis at any of the time points examined.
Moreover, rBMP-2 did not induce adipogenesis in the bone
marrow cavity, as shown by oil red-O staining (data not shown).
Instead, we found that rBMP-2 treatment repressed endogenous
Wnt signaling (Fig. 3). Consequently, Wnt target genes such as
runx2
(64) are also repressed (Fig. 3). Runx2 is required for
osteogenesis,
(65) so the downregulation of runx2 in the rBMP-2-
treated bone marrow cavity is in keeping with the lack of bone
formation in this site.
As mentioned earlier, the ability of rBMP-2 to inhibit
osteogenesis via repression of Wnt pathway activity has a
precedent in fetal skeletal development.
(17) In this context, BMP
signaling in osteoblasts limits bone mass through its action on
sclerostin, which variously functions as an extracellular Wnt
antagonist
(66) and a BMP antagonist
(67) (but see ref.
(68)). We
could not detect a reproducible effect of rBMP-2 treatment on
sclerostin expression in the injury site, but given the pleiotropic
functions of sclerostin/SOST, this may be a transient or subtle
alteration in gene expression that is difficult to detect in an adult
skeletal injury.
rBMP-2 potently stimulates chondrogenic differentiation
in the extracortical space
While rBMP-2 treatment inhibited osteogenesis in the bone
marrow space, the protein had an entirely different effect on
skeletal progenitor cells in the periosteum and extracortical
region. Here, BMP exposure resulted in the upregulation of
collagen type II, the stimulation of alkaline phosphatase activity,
and a robust chondrogenic response (Fig. 5). The molecular
mechanisms behind this robust chondrogenic response were
revealed by analyses of Axin2
LacZ/þ skeletal injuries. rBMP-2
downregulated Wnt activity in the periosteum (Fig. 4), which led
to a derepression of Wnt target gene sox9.
(45) In an embryonic
context, Wnt signaling directly represses sox9,
(45) which allows
osteochondroprogenitor cells to adopt an osteogenic fate.
(39)
Finally, by employing this injury model (Fig. 5), we gained
insights into the mechanism responsible for BMP-mediated
heterotopic ossification.
(12) Specifically, rBMP-2 induces a robust
chondrogenic response from cells in the periosteum and
surrounding soft tissues (Fig. 5; and see refs.
(69) to
(71)), which
leads to the upregulation of sox9 and collagen types I and II and,
Fig. 5. rBMP-2 induces osteochondroprogenitor markers in the supra-
periosteal/muscle compartment. (A) PBS-treated muscle does not exhibit
any Smad 1/5/8 phosphorylation on postoperative day 1. (B) rBMP-2
treatmentinducesphospho-Smad1/5/8immunostaining inthistissueby
day 1 (arrowheads). (C, D) On postoperative day 3, pentachrome staining
of both PBS- and rBMP-2-treated supraperiosteum reveals a highly
cellular region with no overt osteogenesis or chondrogenesis in the
supraperiosteal space. (E) PBS samples do not express collagen type I.(F)
rBMP-2 treatment induces collagen type I expression. (G) PBS-treated
samplesdonotexpresscollagentypeII.(H)rBMP-2inducescollagentypeII
expression here. (I) When the injury is modified to exclude the bone
marrow cavity and separate the periosteal/supraperiosteal compart-
ments, control samples exhibit only fibrous tissue between sponge
and muscle (outlined). (J) rBMP-2-treated samples induce a separate
chondrogenic response from supraperiosteal tissue in the defects.
m¼muscle; spg¼sponge.
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lineage (Fig. 5).
Cell-dependent effects of rBMP-2
Within a single skeletal injury site, cell populations exhibit
dramatically different responses to the same bone-inducing
growth factor. In both the bone marrow cavity and the
periosteum, rBMP-2 treatment represses the endogenous Wnt
pathway, whichis essentialfor intramembranous ossification ina
healing skeletal defect.
(34) How can the different responses be
explained? Some new data suggest that while the periosteum
contains osteochondroprogenitor cells, the endosteum only
supports osteoprogenitor cells.
(52) In embryonic osteochondro-
progenitorcells,Wntsignalingisrequiredfortheirdifferentiation
into osteoblasts,
(45) and when that Wnt signal is blocked,
osteochondroprogenitor cells adopt a chondrogenic fate. In the
endosteum, cells appear to have a more restricted potential;
here,thelackofendogenousWntsignalingcausesthemtoarrest
prior to differentiation into osteoblasts. In vitro, cells derived
from the endosteum and bone marrow have the capacity to
differentiate into chondrocytes.
(72) This capacity is nonexistent
(or repressed) in vivo, and therein may lie an explanation for
the various effects attributed to rBMPs. Clearly, a better
understanding of the in vivo response of skeletal progenitor
cells will lead to improvements in the prochondrogenic and
potentially proosteogenic effects of rBMP-2.
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